{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=8",
    "query": {
      "intervention": "cohort 2",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 7387,
    "total_pages": 739,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T16:16:38.032Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02481297",
      "title": "Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Lirilumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2015-06-23",
      "completion_date": "2019-08-15",
      "has_results": true,
      "last_update_posted_date": "2020-05-28",
      "last_synced_at": "2026-11-17T16:16:38.032Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02481297"
    },
    {
      "nct_id": "NCT04809662",
      "title": "Comparing Immune Responses to Topical Imiquimod",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Actinic Keratoses"
      ],
      "interventions": [
        {
          "name": "Imiquimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 6,
      "start_date": "2021-03-16",
      "completion_date": "2023-11-07",
      "has_results": false,
      "last_update_posted_date": "2024-11-07",
      "last_synced_at": "2026-11-17T16:16:38.032Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04809662"
    },
    {
      "nct_id": "NCT03018405",
      "title": "A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia/Myelodysplastic Syndrome",
        "Multiple Myeloma (MM)"
      ],
      "interventions": [
        {
          "name": "NKR-2 cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Celyad Oncology SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2016-12",
      "completion_date": "2021-08",
      "has_results": false,
      "last_update_posted_date": "2019-09-19",
      "last_synced_at": "2026-11-17T16:16:38.032Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Buffalo, New York",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03018405"
    },
    {
      "nct_id": "NCT07709494",
      "title": "A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants",
        "Non-cystic Fibrosis Bronchiectasis"
      ],
      "interventions": [
        {
          "name": "Rev-56 for Inhalation",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo: Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Revagenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 64,
      "start_date": "2026-07-13",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-11-17T16:16:38.032Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07709494"
    },
    {
      "nct_id": "NCT02201056",
      "title": "Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-935",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2014-07",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-11-17T16:16:38.032Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02201056"
    },
    {
      "nct_id": "NCT03900923",
      "title": "Cannabidiol for ASD Open Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ASD",
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "98% pure CBD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 29,
      "start_date": "2019-03-12",
      "completion_date": "2023-05-04",
      "has_results": true,
      "last_update_posted_date": "2024-05-31",
      "last_synced_at": "2026-11-17T16:16:38.032Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03900923"
    },
    {
      "nct_id": "NCT04402866",
      "title": "TD-0903 for ALI Associated With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lung Injury (ALI) Associated With COVID-19",
        "Lung Inflammation Associated With COVID-19"
      ],
      "interventions": [
        {
          "name": "TD-0903",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theravance Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 235,
      "start_date": "2020-06-24",
      "completion_date": "2021-04-21",
      "has_results": true,
      "last_update_posted_date": "2022-03-17",
      "last_synced_at": "2026-11-17T16:16:38.032Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Denver, Colorado • Sebring, Florida + 9 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sebring",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Fall River",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04402866"
    },
    {
      "nct_id": "NCT01853631",
      "title": "Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Acute Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells",
          "type": "GENETIC"
        },
        {
          "name": "Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 64,
      "start_date": "2014-02",
      "completion_date": "2036-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-11-17T16:16:38.032Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853631"
    },
    {
      "nct_id": "NCT01829724",
      "title": "Cerebral Palsy and the Study of Brain Activity During Motor Tasks",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cerebral Palsy",
        "Children"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "5 Years to 100 Years"
      },
      "enrollment_count": 320,
      "start_date": "2013-08-22",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-11-17T16:16:38.032Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01829724"
    },
    {
      "nct_id": "NCT06265727",
      "title": "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "CRB-701",
          "type": "DRUG"
        },
        {
          "name": "Anti-PD-1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corbus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 348,
      "start_date": "2024-04-01",
      "completion_date": "2027-01-27",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-11-17T16:16:38.032Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Duarte, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06265727"
    }
  ]
}